Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Mar Drugs
2020 Sep 29;1810:. doi: 10.3390/md18100496.
Show Gene links
Show Anatomy links
Hp-s1 Ganglioside Suppresses Proinflammatory Responses by Inhibiting MyD88-Dependent NF-κB and JNK/p38 MAPK Pathways in Lipopolysaccharide-Stimulated Microglial Cells.
Shih JH
,
Tsai YF
,
Li IH
,
Chen MH
,
Huang YS
.
???displayArticle.abstract???
Hp-s1 ganglioside is isolated from the sperm of sea urchin (Hemicentrotus pulcherrimus). In addition to neuritogenic activity, the biological function of Hp-s1 in neuroinflammation is unknown. In this study, we investigated the anti-neuroinflammatory effect of Hp-s1 on lipopolysaccharide (LPS)-stimulated microglial cells. MG6 microglial cells were stimulated with LPS in the presence or absence of different Hp-s1 concentrations. The anti-inflammatory effect and underlying mechanism of Hp-s1 in LPS-activated microglia cells were assessed through a Cell Counting kit-8 assay, Western blot analysis, and immunofluorescence. We found that Hp-s1 suppressed not only the expression of inducible nitric oxide synthase and cyclooxygenase-2 but also the expression of proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6. Hp-s1 inhibited the LPS-induced NF-κB signaling pathway by attenuating the phosphorylation and translocation of NF-κB p65 and by disrupting the degradation and phosphorylation of inhibitor κB-α (IκBα). Moreover, Hp-s1 inhibited the LPS-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK). Hp-s1 also reduced the expression of myeloid differentiation factor 88 (MyD88) and TNF receptor-associated factors 6 (TRAF6), which are prerequisites for NF-κB and MAPKs activation. These findings indicated that Hp-s1 alleviated LPS-induced proinflammatory responses in microglial cells by downregulating MyD88-mediated NF-κB and JNK/p38 MAPK signaling pathways, suggesting further evaluation as a new anti-neuroinflammatory drug.
Figure 1. Effect of Hp-s1 ganglioside on cell viability of MG6 microglial cells. The cells were cultured with different Hp-s1 concentrations (5â100 μM) for 24 h. The cell viability was determined via a CCK-8 assay. Quantitative data were expressed as the percentage of the corresponding untreated control value (mean ± S.D., n = 3, quadruplicate wells for each condition).
Figure 2. Hp-s1 suppresses the lipopolysaccharide (LPS)-induced expression of iNOS and COX-2 in a dose-dependent manner. (A) The cells were pretreated with Hp-s1 (5, 15, or 30 μM) for 2 h and then treated with or without LPS (1âμg/mL) for another 8 h. Total lysates were collected, and the protein levels of iNOS and COX-2 were detected via Western blot analysis. β-actin was used as an internal control. (B) The protein bands of each regimen were quantified through densitometry. Data were expressed as the percentage of the LPS-treated group (mean ± S.D., n = 3). ##
p < 0.01 vs. the control group; ** p < 0.01 vs. the LPS-treated group. (C) Immunofluorescence staining for iNOS and COX-2. Cells were pretreated with 30 μM Hp-s1 for 2 h and then stimulated with or without LPS (1 μg/mL) for 8 h. The cells were immunostained with anti-iNOS and anti-COX-2 antibodies. The nuclei (blue) were stained with 4â²,6-diamidino-2-phenylindole (DAPI). Bar = 30 μm.
Figure 3. Hp-s1 suppresses proinflammatory cytokines in LPS-stimulated microglial cells. (A) The cells were pretreated with different Hp-s1 concentrations (5, 15, or 30 μM) in the absence or presence of LPS (1 μg/mL) for 8 h and then subjected to Western blot analysis with anti-TNF-α, anti-IL-1β, and IL-6 antibodies; β-actin was used as an internal control. (B) The protein bands of each regimen were quantified via densitometry. Data were expressed as the percentage of the LPS-treated group (mean ± S.D., n = 3). ##
p < 0.01 vs. the control group; * p < 0.05 and ** p < 0.01 vs. the LPS-treated group. (C) Immunofluorescence staining for TNF-α. and IL-6. The cells were pretreated with 30 μM Hp-s1 for 2 h and then stimulated with or without LPS (1 μg/mL) for 8 h. The cells were immunostained with anti-TNF-α and IL-6 antibodies. The nuclei (blue) were stained with DAPI. Bar = 30 μm.
Figure 4. Hp-s1 inhibits the LPS-induced NF-κB activation. (A) The cells were pretreated with different Hp-s1 concentrations (5, 15, or 30 μM) for 2âh and then stimulated with LPS (1 μg/mL) for 1âh. Cell lysates were subjected to Western blot to determine the protein levels of p-p65, p65, p-IκBα, and IκBα. β-actin was used as an internal control. (B) The protein bands of each regimen were quantified via densitometry. Data were expressed as the percentage of the LPS-treated group (mean ± S.D., n = 3). ##
p < 0.01 vs. the control group; * p < 0.05 and ** p < 0.01 vs. the LPS-treated group. (C) Immunofluorescence analysis of NF-κB translocation. The cells were pretreated with Hp-s1 (30 μM) for 2 h and then activated with LPS (1 μg/mL) for 1 h. The translocation of the p65 subunit of NF-κB was determined via immunocytochemistry using anti-p65 NF-κB antibody. The nuclei (blue) were stained with DAPI. Scale bar = 30 μm.
Figure 5. Hp-s1 inhibits the LPS-induced JNK/p38 MAPK activation. (A) The cells were pretreated with different Hp-s1 concentrations (5, 15, or 30 μM) for 2âh and then stimulated with or without LPS (1 μg/mL) for 1 h. Cell lysates were subjected to Western blot to determine the protein levels of MAPKs (p-p38/p38, p-JNK/JNK, and p-ERK/ERK). β-actin was used as an internal control. (BâD) The protein bands of each regimen were quantified via densitometry. Data were expressed as the percentage of the LPS-treated group (mean ± S.D., n = 3). ##
p < 0.01 and á´ª
p < 0.05 vs. the control group; * p < 0.05 and ** p < 0.01 vs. the LPS-treated group.
Figure 6. Hp-s1 blocks the LPS-induced MyD88/TRAF6-dependent signaling pathway in MG6 microglial cells. (A) The cells were pretreated with different Hp-s1 concentrations (5, 15, or 30 μM) for 2 h and then stimulated with or without LPS (1 μg/mL) for 40 min. Cell lysates were subjected to Western blot to determine the protein levels of TLR4, MyD88, and TRAF6. β-actin was used as an internal control. (BâD) The protein bands of each regimen were quantified via densitometry. Data were expressed as the percentage of the LPS-treated group (mean ± S.D., n = 3). ##
p < 0.01 vs. the control group; * p < 0.05 vs. the LPS-treated group.
Figure 7. Schematic of the anti-inflammatory action of Hp-s1. Hp-s1 inhibited the proinflammatory reactions in MG6 microglial cells by repressing the MyD88/TRAF6-dependent NF-κB and JNK/p38 MAPK signaling pathways.
Azam,
Regulation of Toll-Like Receptor (TLR) Signaling Pathway by Polyphenols in the Treatment of Age-Linked Neurodegenerative Diseases: Focus on TLR4 Signaling.
2019, Pubmed
Azam,
Regulation of Toll-Like Receptor (TLR) Signaling Pathway by Polyphenols in the Treatment of Age-Linked Neurodegenerative Diseases: Focus on TLR4 Signaling.
2019,
Pubmed
Bachstetter,
The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.
2010,
Pubmed
Benvenuti,
Corticosteroid-induced osteoporosis: pathogenesis and prevention.
2000,
Pubmed
Catorce,
LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals.
2016,
Pubmed
Cunningham,
Microglia and neurodegeneration: the role of systemic inflammation.
2013,
Pubmed
Du,
Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target.
2017,
Pubmed
Duchemin,
GM1 ganglioside induces phosphorylation and activation of Trk and Erk in brain.
2002,
Pubmed
Dukhinova,
Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer's disease.
2019,
Pubmed
Furukawa,
Novel Molecular Mechanisms of Gangliosides in the Nervous System Elucidated by Genetic Engineering.
2020,
Pubmed
Furukawa,
Regulatory function of glycosphingolipids in the inflammation and degeneration.
2015,
Pubmed
Garofalo,
Ganglioside GM3 activates ERKs in human lymphocytic cells.
2002,
Pubmed
Guzman-Martinez,
Neuroinflammation as a Common Feature of Neurodegenerative Disorders.
2019,
Pubmed
Han,
p38 mitogen-activated protein kinase mediates lipopolysaccharide, not interferon-gamma, -induced inducible nitric oxide synthase expression in mouse BV2 microglial cells.
2002,
Pubmed
Harry,
Microglia during development and aging.
2013,
Pubmed
Ijuin,
Isolation and identification of novel sulfated and nonsulfated oligosialyl glycosphingolipids from sea urchin sperm.
1996,
Pubmed
,
Echinobase
Jeong,
Anti-inflammatory effects of α-galactosylceramide analogs in activated microglia: involvement of the p38 MAPK signaling pathway.
2014,
Pubmed
Jou,
Gangliosides trigger inflammatory responses via TLR4 in brain glia.
2006,
Pubmed
Kempuraj,
Neuroinflammation Induces Neurodegeneration.
2016,
Pubmed
Kim,
Compromised MAPK signaling in human diseases: an update.
2015,
Pubmed
Kim,
Isorhamnetin alleviates lipopolysaccharide-induced inflammatory responses in BV2 microglia by inactivating NF-κB, blocking the TLR4 pathway and reducing ROS generation.
2019,
Pubmed
Kopitar-Jerala,
Innate Immune Response in Brain, NF-Kappa B Signaling and Cystatins.
2015,
Pubmed
Lee,
Toll-like receptors and inflammation in the CNS.
2002,
Pubmed
Leitner,
Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders.
2019,
Pubmed
Li,
TRAF6-p38/JNK-ATF2 axis promotes microglial inflammatory activation.
2019,
Pubmed
Magistretti,
Gangliosides: Treatment Avenues in Neurodegenerative Disease.
2019,
Pubmed
Nakamichi,
Roles of NF-kappaB and MAPK signaling pathways in morphological and cytoskeletal responses of microglia to double-stranded RNA.
2007,
Pubmed
Nikolaeva,
GM1 and GD1a gangliosides modulate toxic and inflammatory effects of E. coli lipopolysaccharide by preventing TLR4 translocation into lipid rafts.
2015,
Pubmed
Ohmi,
Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues.
2009,
Pubmed
Ohmi,
Gangliosides are essential in the protection of inflammation and neurodegeneration via maintenance of lipid rafts: elucidation by a series of ganglioside-deficient mutant mice.
2011,
Pubmed
O'Neill,
Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily.
2002,
Pubmed
O'Neill,
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling.
2007,
Pubmed
O'Neill,
Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors.
2003,
Pubmed
Park,
Ganglioside GM3 suppresses lipopolysaccharide-induced inflammatory responses in rAW 264.7 macrophage cells through NF-κB, AP-1, and MAPKs signaling.
2018,
Pubmed
Peppa,
Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review.
2011,
Pubmed
Pyo,
Gangliosides activate cultured rat brain microglia.
1999,
Pubmed
Rahimifard,
Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for neuroinflammation.
2017,
Pubmed
Schnaar,
Gangliosides of the Vertebrate Nervous System.
2016,
Pubmed
Schnaar,
The Biology of Gangliosides.
2019,
Pubmed
Shabab,
Neuroinflammation pathways: a general review.
2017,
Pubmed
Shelke,
Synthesis and Bioassay of Neurogenically Potent Gangliosides DSG-A, Hp-s1 and Their Analogues.
2018,
Pubmed
Shen,
MAP kinase regulation of IP10/CXCL10 chemokine gene expression in microglial cells.
2006,
Pubmed
Subedi,
Anti-Inflammatory Effect of Sulforaphane on LPS-Activated Microglia Potentially through JNK/AP-1/NF-κB Inhibition and Nrf2/HO-1 Activation.
2019,
Pubmed
Takenouchi,
Inhibitory effects of U73122 and U73343 on Ca2+ influx and pore formation induced by the activation of P2X7 nucleotide receptors in mouse microglial cell line.
2005,
Pubmed
Tsai,
The total synthesis of a ganglioside Hp-s1 analogue possessing neuritogenic activity by chemoselective activation glycosylation.
2012,
Pubmed
Tsai,
Ganglioside Hp-s1 Analogue Inhibits Amyloidogenic Toxicity in Alzheimer's Disease Model Cells.
2019,
Pubmed
Walters,
An Overview of Nonsteroidal Antiinflammatory Drug Reactions.
2016,
Pubmed
Wang,
Ganglioside GD1a suppresses LPS-induced pro-inflammatory cytokines in RAW264.7 macrophages by reducing MAPKs and NF-κB signaling pathways through TLR4.
2015,
Pubmed
Wu,
Assistance of the C-7,8-Picoloyl Moiety for Directing the Glycosyl Acceptors into the α-Orientation for the Glycosylation of Sialyl Donors.
2017,
Pubmed
Zhao,
Bacteroidetes Neurotoxins and Inflammatory Neurodegeneration.
2018,
Pubmed
Zusso,
Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway.
2019,
Pubmed